Voronoi In Spotlight For Brain-Permeable Lung Cancer Candidate

Korean Venture Building Platforms, Eyes IPO

 
• By Jung Won Shin

South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.

Digital illustration of lung cancer cells in color background - Illustration
Will Voronoi's NSCLC Drug Candidate Hit A Home Run? • Source: Shutterstock

More from South Korea

More from Focus On Asia